首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Evaluation of the updated deifnition of early allograftdysfunctionindonationafterbraindeath and donation after cardiac death liver allografts
【24h】

Evaluation of the updated deifnition of early allograftdysfunctionindonationafterbraindeath and donation after cardiac death liver allografts

机译:对脑死亡后的早期同种异体移植功能障碍和心源性肝移植后的捐赠的更新定义的评估

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: An  updated  deifnition  of  early  allograft dysfunction (EAD) was recently validated in a multicenter study of 300 deceased donor liver transplant recipients. This analysis did not differentiate between donation after brain death (DBD) and donation after cardiac death (DCD) allograft recipients. METHODS: We reviewed our prospectively entered database for all DBD (n=377) and DCD (n=38) liver transplantations between January 1, 2006 and October 30, 2011. The incidence of EAD as well as its ability to predict graft failure and survival was compared between DBD and DCD groups. RESULTS: EAD was a valid predictor of both graft and patient survival at six months in DBD allograft recipients, but in DCD allograft recipients there was no signiifcant difference in the rate of graft failure in those with EAD (11.5%) compared with those without EAD (16.7%) (P=0.664) or in the rate of death in recipients with EAD (3.8%) compared with those without EAD (8.3%) (P=0.565). The graft failure rate in the ifrst 6 months in those with international normalized ratio ≥1.6 on day 7 who received a DCD allograft was 37.5% compared with 6.7% for those with international normalized ratio <1.6 on day 7 (P=0.022). CONCLUSIONS: The recently validated deifnition of EAD is a valid predictor of patient and graft survival in recipients of DBD allografts. On initial assessment, it does not appear to be a useful predictor of patient and graft survival in recipients of DCD allografts, however a study with a larger sample size of DCD allografts is needed to conifrm these ifndings. The high ALT/AST levels in most recipients of DCD livers as well as the predisposition to biliary complications and early cholestasis make these parameters as poor predictors of graft failure. An alternative deifnition of EAD that gives greater weight to the INR on day 7 may be more relevant in this population.
机译:背景:早期的同种异体移植功能障碍(EAD)的最新定义已在多中心研究中对300名已死亡的供体和肝移植受者进行了最近的验证。这种分析在脑死亡(DBD)后的捐赠与心脏死亡(DCD)同种异体移植后的捐赠之间没有区别。 方法:我们回顾了我们为所有DBD(n = 377)和DCD(n = 38)在2006年1月1日至2011年10月30日之间进行的肝移植所输入的数据库。EAD发生的可能性以及其发生的可能性在DBD组和DCD组之间比较了移植物的失败和存活率。 结果:EAD对DBD异体移植接受者在六个月内都是移植物和患者存活率的有效预测者,但在DCD中异体移植接受者的接受率却没有明显的差别(11%)。那些没有EAD的人(16.7%)(P = 0.664)或与没有EAD的收件人的死亡率(3.8%)相比,那些没有EAD的死亡率(8.3%)(P = 0.565)。那些在国际标准化归一化比率≥1.6的国家中,在最初的6个月中的移植失败率是7%,而DCD的国际化比率是6.7,而在国际标准化度为= 0的情况下,接受DCD的国家/地区的比率为6.7%,而在D = 0。 结论:最近对EAD的定义是对DBD同种异体移植患者的耐心生存和移植存活率的有效预测指标。在初始评估中,它似乎并没有成为DCD替代移植患者中有用的患者和移植存活率的有效预测指标,但是,如果研究的结果是较大的DCD替代的样本,则需要进行较大的抽样研究。 DCD的大多数接受者的高ALT / AST水平与胆道并发症的易感性以及早期胆汁淤积症有关,这些参数可能是导致移植物衰竭的较差指标。 EAD的另一种定义是,在此人口中,第7天的权重可能会更大,从而使INR具有更大的相关性。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2012年第004期|372-376|共5页
  • 作者单位

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

    Multi-0rgan Transplant Program, London Health Sciences Centre Croome KP, Wall W, Quan D, Vangala S, McAlister V, Marotta P and Hernandez-Alejandro R and Department of Surgery, Division of General Surgery Croome KP, Wall W, Quan D, McAlister V and Hernandez-Alejandro R and Division of Gastroenterology Marotta P, The University of Western 0ntario, London, Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号